FDA releases draft guidance for natural history studies

Addressing a challenge in the development of rare disease treatments, FDA published draft guidance on Friday to help drug companies and patient

Read the full 227 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE